These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 9218165)

  • 21. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.
    Wetzel H; Gründer G; Hillert A; Philipp M; Gattaz WF; Sauer H; Adler G; Schröder J; Rein W; Benkert O
    Psychopharmacology (Berl); 1998 Jun; 137(3):223-32. PubMed ID: 9682999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol.
    de Bartolomeis A; Marmo F; Buonaguro EF; Rossi R; Tomasetti C; Iasevoli F
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1516-29. PubMed ID: 23357084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in effects of sultopride and sulpiride on dopamine turnover in rat brain.
    Moriuchi K; Imazu Y; Yoneda H
    Neurochem Res; 1995 Jan; 20(1):95-9. PubMed ID: 7739765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current use of atypical antipsychotics.
    Müller-Spahn F
    Eur Psychiatry; 2002 Aug; 17 Suppl 4():377s-384s. PubMed ID: 23573608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride.
    Stone JM; Bressan RA; Erlandsson K; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2005 Aug; 180(4):664-9. PubMed ID: 15719226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carmoxirole is able to reduce amisulpride-induced hyperprolactinemia without affecting its central effect.
    Marchese G; Ruiu S; Casti P; Bartholini F; Saba P; Gessa GL; Pani L
    Eur J Pharmacol; 2002 Jun; 447(1):109-14. PubMed ID: 12106810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of 50mg amisulpride on EEG, psychomotor and cognitive functions in healthy sleep-deprived subjects.
    Patat A; Rosenzweig P; Miget N; Allain H; Gandon JM
    Fundam Clin Pharmacol; 1999; 13(5):582-94. PubMed ID: 10520732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological profile of MS-377, a novel antipsychotic agent with selective affinity for sigma receptors.
    Takahashi S; Sonehara K; Takagi K; Miwa T; Horikomi K; Mita N; Nagase H; Iizuka K; Sakai K
    Psychopharmacology (Berl); 1999 Aug; 145(3):295-302. PubMed ID: 10494578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respective roles of dopamine D2 and D3 receptors in food-seeking behaviour in rats.
    Duarte C; Biala G; Le Bihan C; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2003 Feb; 166(1):19-32. PubMed ID: 12525958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amisulpride: progress and outcomes.
    Lecrubier Y
    Curr Med Res Opin; 2002; 18 Suppl 3():s18-22. PubMed ID: 12418608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intrastriatal infusion of D2 receptor antisense oligonucleotide on apomorphine-induced behaviors in the rat.
    Rajakumar N; Laurier L; Niznik HB; Stoessl AJ
    Synapse; 1997 Jul; 26(3):199-208. PubMed ID: 9183809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.